EUROPARLed by Prof K Ray Chaudhuri, EUROPAR is a multidisciplinary group that was formed to perform “real life” non-motor based clinical studies across a wide range of people with Parkinson’s throughout Europe. The main aim of EUROPAR is to pursue studies as they happen in real life and described as a “holistic” natural history study in Parkinson’s. The study will additionally include people with Parkinson’s who are often excluded from clinical trials e.g. due to their age.

EUROPAR focuses on translational ‘bench to bedside’ research (for example, looking at what impact ‘real life’ treatments such as skin patches, injections and infusions may have on the non-motor aspects of Parkinson’s) and the development of better patient and public involvement in the treatment of Parkinson’s disease.

The main EUROPAR project is a longitudinal study in Parkinson’s (NILS: Non-motor Longitudinal International Study), a global study addressing non-motor profiling of Parkinson’s and natural history of non-motor symptoms together with treatment response and clinico-pathological correlations. This project has been adopted by the Department of Health in the UK (NIHR: National Institute of Health Research) and also supported by the Spanish ministry of education and the Biomedical Research Centre (Dementia) at King’s College.

EUROPAR is a partner of European Parkinson’s Disease Association as well as part of International Parkinson’s and Movement Disorders Society Parkinson’s Non Motor Study Group.


CRISP (Community for Research Involvement and Support by PwPs) is the EUROPAR expert patient group formed to promote PPI (public and patient involvement).

The purpose of CRISP is to raise awareness of research, highlight the importance of participation of people (specifically with Parkinson’s) in clinical research, and encourage patients and their carers to ask about clinical research when with their consultant.

Read more

EUROPAR involves 14 centres across Europe while the international non motor research group led from King’s involves 34 centres worldwide.

NILS Group members
  • Pablo Martinez-Martin and Carmen Rodriguez-Blazquez (National Centre of Epidemiology and CIBERNED, Carlos III Institute of Health. Madrid, Spain)
  • Ray Chaudhuri, Alexandra Rizos, Anna Sauerbier, Miriam Parry, Dhaval Trivedi, Lauren Perkins and Marios Politis (Kings College Hospital and University Hospital Lewisham. London, UK)
  • Davide Martino (Kings College and Woolwich Hospitals);
  • Per Odin (Department of Neurology, Lund University Hospital, Lund, Sweden and Central Hospital Bremerhaven, Germany)
  • Angelo Antonini (Department for Parkinson’s Disease, IRCCS San Camillo. Venice, Italy)
  • Fabrizio Stocchi (Department of Neurology, IRCCS San Raffaele. Rome, Italy)
  • Jacobus J. van Hilten (Department of Neurology, Leiden University Medical Center. Leiden, The Netherlands)
  • Teus van Laar (University of Groningen, Groningen, The Netherlands)
  • Cristian Falup‐Pecurariu (Department of Neurology, Faculty of Medicine, Transilvania University. Braşov, Romania)
  • Espen Dietrichs (Oslo University Hospital, Oslo, Norway)
  • Kelly E. Lyons (University of Kansas Medical Center. Kansas City, Kansas, US)
  • Dan Weintraub (Hospital of the University of PA, Philadelphia, USA)
  • Monica Kurtis (Movement Disorders Program, Department of Neurology. Hospital RuberInternacional. Madrid, Spain)
  • Marcos Serrano-Dueñas (Movement Disorder and Biostatistic Units, Neurological Service, Carlos Andrade Marín Hospital. Quito, Ecuador)
  • Vanderci Borges (Movement Disorders Section, Department of Neurology, Universidade Federal de São Paulo. São Paulo, Brazil)
  • Madhuri Behari (Department of Neurology, All India Institute of Medical Sciences. New Delhi, India)
  • Kalyan Bhattacharya and Hrishikesh Kumar (RG Kar Medical College and Institute of Neuroscience , Kolkata, India)
  • Bhim Singhal (Bombay Hospital Institute of Medical Sciences, Mumbai, India)
  • Roongroj Bhidayasiri (Chulalongkorn University Hospital , Bangkok, Thailand)
  • Lim Shen-Yang (University of Malaya, Kualalampur, Malaysia)
  • Marisol Gallardo (Hospital Dr. Domingo Luciani. Caracas, Venezuela)
  • Kazuo Abe (Hyogo Medical College, Nishinomiya, Japan)
  • Sevasti Bostantjopoulou (Third Department of Neurology, Aristotle University of Thessaloniki. Thessaloniki, Greece)
  • Jose Martin Rabey (Department of Neurology, AssafHarofeh Medical Center, Tel Aviv University. Zerifin, Israel)
  • Federico Micheli (Parkinson’s Disease and Other Movement Disorders Unit, Hospital de Clinicas Jose de San Martin. Buenos Aires, Argentina)
  • Mayela Rodriguez‐Violante (Movement Disorders Unit, Instituto Nacional de Neurologia y Neurocirugía. Mexico DF, Mexico)
  • Giulio Riboldazzi (Macchi Foundation, Varese and Department of Rehabilitation, Le Terrazze Hospital. Cunardo, Italy)
  • Maria Jose Catalan (Hospital Clinico San Carlos. Madrid, Spain)
  • Cathy Ellis and Lorna Bean (Medway Maritime Hospital. Kent, UK)
  • Belinda Kessel (Princess Royal University Hospital, King’s College Hospital. Orpington, UK)
  • Paul Worth and Gemma Shearing (Department of Neurology, Norfolk and Norwich University Hospital. Norwich, and Addenbrook Hospital, Cambridge, UK)
  • Rani Sophia (Yeovil Hospital NHS Foundation Trust. Somerset, UK)
  • Jagdish Sharma (United Lincolnshire Hospitals NHS Trust. Lincoln, UK)
  • Monty Silverdale (Salford Royal NHS Foundation Trust. Manchester, UK)
  • Suvankar Pal (Forth Valley Royal Hospital. Edinburgh, UK)
  • Keyoumars Ashkan (King’s College Hospital, London, UK)

Other EUROPAR projects

Alongside the NILS study, EUROPAR is also running some smaller projects addressing various topics. Study results have been presented at international congresses and details of poster presentations, each of which can be accessed here.